| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 4500 |
| 001 |
in00005773564 |
| 005 |
20260327180136.3 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
231115s2023 xx o ||| 0 eng d |
| 040 |
|
|
|a SFB
|b eng
|e rda
|e pn
|c SFB
|d OCLCO
|d OCLCQ
|d OCLCL
|
| 020 |
|
|
|a 0443192944
|
| 020 |
|
|
|a 9780443192944
|
| 020 |
|
|
|a 0443192952
|
| 020 |
|
|
|a 9780443192951
|
| 035 |
|
|
|a (OCoLC)1450403171
|
| 082 |
1 |
4 |
|a 616.0756
|
| 049 |
|
|
|a TXAM
|
| 100 |
1 |
|
|a Makowski, Gregory S.
|
| 245 |
1 |
0 |
|a Advances in Clinical Chemistry. Volume 117.
|
| 250 |
|
|
|a 1st ed.
|
| 260 |
|
|
|b Elsevier
|c 2023.
|
| 300 |
|
|
|a 1 online resource (232 p.).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Issn Series ;
|v v.Volume 117
|
| 520 |
|
|
|a Advances in Clinical Chemistry, Volume 117, the latest installment in this internationally acclaimed series, contains chapters authored by world-renowned clinical laboratory scientists, physicians and research scientists.
|
| 505 |
0 |
|
|a Front Cover -- Advances in Clinical Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Viscoelastic Testing Methods -- 1 Introduction -- 2 Physiology of hemostasis in VET -- 2.1 Shear force modulus -- 3 History -- 4 Current methods -- 4.1 Pre-analytic considerations -- 4.2 Legacy platforms (TEG 5000, ROTEM Delta, ClotPro, Sonoclot) -- 4.3 Cartridge-based platforms (TEG 6S, ROTEM Sigma, Hemosonics Quantra) -- 4.4 Platelet function testing -- 4.5 Other VET technologies -- 5 Interpretation of VET results -- 5.1 Legacy parameters -- 5.2 Quantra -- 5.3 Common patterns -- 6 Clinical applications -- 6.1 Identification of hemostatic factor deficiencies/transfusion therapy -- 6.2 Monitoring of anticoagulation -- 6.3 Identification of hypercoagulable states -- 6.4 Detection of hyperfibrinolysis -- 6.5 Limitations -- 6.6 VETs vs CCTs -- 7 Practice settings -- 7.1 Trauma -- 7.2 Liver transplant surgery -- 7.3 Cardiac surgery -- 7.4 Obstetrics -- 7.5 Oncology -- 7.6 Benign hematology -- 8 Conclusion -- Acknowledgments -- References -- Chapter Two: The role of sRAGE in cardiovascular diseasesThe role of sRAGE in cardiovascular diseases -- 1 Introduction -- 2 Atherosclerosis -- 2.1 Relationship between RAGE and atherosclerosis -- 2.2 Hypothesis -- 3 Coronary artery disease -- 3.1 Relationship between RAGE and coronary artery disease -- 3.2 Hypothesis -- 4 Heart failure -- 4.1 Relationship between RAGE and heart failure -- 4.2 Hypothesis -- 5 Conclusions -- References -- Chapter Three: Advances in preeclampsia testing -- 1 Introduction amp -- #x0026 -- clinical definitions -- 1.1 Chronic (pre-existing) hypertension -- 1.2 Gestational hypertension -- 1.3 Preeclampsia-eclampsia -- 1.4 Chronic hypertension with superimposed preeclampsia -- 2 Characteristics of preeclampsia.
|
| 505 |
8 |
|
|a 2.1 Pathophysiology and role of angiogenic factors in the pathogenesis of preeclampsia -- 2.1.1 Phase 1: Trophoblastic invasion and abnormal placentation -- 2.1.2 Phase 2: Maternal syndrome and angiogenic imbalance -- 2.2 Clinical manifestations and adverse outcomes -- 2.2.1 Hypertension -- 2.2.2 Renal dysfunction -- 2.2.3 Proteinuria -- 2.2.4 Neurologic abnormalities -- 2.2.5 Hepatic dysfunction -- 2.2.6 Hematologic dysfunction -- 2.2.7 Maternal risk factors -- 2.3 Management of preeclampsia -- 2.3.1 Treatment of preeclampsia -- 2.3.2 First trimester screening for preeclampsia -- 3 Clinical guideline recommendations and laboratory testing for preeclampsia screening -- 3.1 Preeclampsia diagnostic criteria -- 3.2 Maternal risk factors for preeclampsia -- 3.3 PlGF-based testing to screen for preeclampsia in the first trimester -- 3.4 PlGF-based testing to rule in and rule out preeclampsia in the second and third trimesters -- 4 Analytical and clinical perspectives on PlGF and sFlt-1 testing -- 4.1 Automated immunoassays for PlGF and sFlt-1 measurement -- 4.1.1 Elecsys PlGF and sFlt-1 assays -- 4.1.1.1 Analytical principle -- 4.1.1.2 Analytical performance and considerations -- 4.1.1.3 Clinical performance -- 4.1.2 DELFIA immunoassay systems -- 4.1.2.1 Analytical principle -- 4.1.2.2 Analytical performance and considerations -- 4.1.2.3 Clinical performance -- 4.1.3 KRYPTOR PlGF and sFlt-1 assay -- 4.1.3.1 Analytical principle -- 4.1.3.2 Analytical performance and considerations -- 4.1.3.3 Clinical performance -- 4.2 Point of care quantitative PlGF assay -- 4.2.1 Analytical principle -- 4.2.2 Analytical performance and considerations -- 4.2.3 Clinical performance -- 4.3 Analytical variations between assays on different platforms -- 4.3.1 PlGF and sFlt-1 assays may detect different isoforms -- 4.3.2 BRAHMS Kryptor vs Roche Elecsys.
|
| 505 |
8 |
|
|a 4.3.3 BRAHMS Kryptor vs Roche Elecsys vs Perkin/Elmer DELFIA PlGF 1-2-3 -- 5 Future research directions -- 6 Summary -- Acknowledgment -- References -- Chapter Four: Immunohematological testing and transfusion management of the prenatal patientPrenatal testing and transfusion -- 1 Introduction -- 2 Red cell antigens and antibodies -- 3 Maternal red cell alloimmunization -- 4 Hemolytic disease of the fetus and newborn -- 4.1 ABO antibodies -- 4.2 Anti-D antibodies -- 4.3 Anti-K antibodies -- 5 Routine immunohematological testing of the prenatal patient -- 5.1 Patient history -- 5.2 Sample -- 5.3 When to test -- 5.4 ABO and D typing -- 5.5 Antibody screen and antibody identification [54-56] -- 6 Testing for prenatal patients with significant red cell antibodies -- 6.1 Antibody titration -- 6.2 Paternal testing -- 6.3 Fetal antigen typing [58,59] -- 6.4 Assessment of FMH [63,64] -- 7 Preparing RBC units for fetal transfusions -- 7.1 Source -- 7.2 Age -- 7.3 Blood type -- 7.4 Phenotype match -- 7.5 Hemoglobin S -- 7.6 Anticoagulant/preservative solution -- 7.7 CMV risk-reduction -- 7.8 Volume and Hct -- 7.9 Timing of irradiation -- 7.10 Record-keeping -- 8 Immunohematological testing of the newborn [82-87] -- 8.1 ABO-Rh typing -- 8.2 DAT and eluate testing [91] -- 9 Pregnancy arising from assisted reproductive technology -- 10 Unresolved questions in prenatal immunohematology -- 10.1 Which common red cell antibodies may be disregarded during pregnancy? -- 10.2 Should the antibody screen be repeated in an uneventful pregnancy? -- 10.3 How should reagent cells for antibody titration be selected? -- 10.4 What is the critical titer for maternal anti-K? -- 10.5 How should prenatal patients with anti-M be managed? -- 10.6 Should RBC units for routine transfusion of women with child-bearing potential be K-negative? -- 11 Case studies.
|
| 505 |
8 |
|
|a 11.1 Anti-D antibody:Immune or passive? -- 11.2 Anti-D plus anti-C, or anti-G antibody? -- 11.3 Antibody against a high-prevalence antigen: Anti-U antibody -- 11.4 Antibody against a low-prevalence antigen: Anti-Cw antibody -- 11.5 Autoantibodies -- 11.6 Nonspecific serological reactivity -- 12 Future prospects -- References -- Chapter Five: Lead poisoning: Clinical and laboratory considerations -- 1 Introduction and historical background -- 2 Clinical effects of lead exposure -- 2.1 Pathophysiology -- 2.1.1 Routes of exposure -- 2.1.2 Cellular mechanisms of lead toxicity -- 2.2 Clinical symptoms in adults -- 2.3 Clinical symptoms in children -- 2.4 Physical and laboratory findings in lead exposure -- 3 Lead screening -- 4 Methods for the detection of lead in the body -- 5 Summary -- References -- Chapter Six: Advances in clinical chemistry patient-based real-time quality control (PBRTQC) -- 1 Introduction -- 2 Quality control -- 2.1 Problems with conventional QC -- 3 Patient-based real-time quality control -- 3.1 The population(s) -- 3.2 Algorithm selection -- 3.3 Control limits -- 3.4 Treatment of outliers -- 4 PBRTQC techniques -- 4.1 Average of normals (AoN) -- 4.2 Moving average (MA) -- 5 Exponentially adjusted weighted moving mean (EAMM), trend (T)EAMM, and Bull's algorithm -- 5.1 Regression-adjusted real-time quality control (RARTQC) -- 5.2 Moving median -- 5.3 Moving quartile (MQ) -- 5.4 Moving standard deviation (MovSD) -- 5.5 Percentage of the reference interval outliers -- 5.6 The moving sum of the number of flagged patients results (MovSO) -- 5.7 Average of delta (AOD) -- 6 Statistical procedures and performance metrics -- 6.1 Transformations -- 6.1.1 Box-Cox transformation -- 6.2 Simulation methods -- 6.3 Simulated annealing algorithm -- 7 PBRTQC on multiple analyzers -- 8 Optimization techniques -- 9 Information technology and software.
|
| 505 |
8 |
|
|a 10 Monitoring PBRTQC by technologists in a live environment -- 10.1 Applying PBRTQC concepts on conventional QC data -- 11 Validation and verification -- 12 Integration with practice and examples -- 13 Advantages and disadvantages -- 14 The future -- 15 Conclusion -- References -- Index -- Back Cover.
|
| 650 |
|
0 |
|a Clinical chemistry.
|
| 650 |
|
2 |
|a Chemistry, Clinical
|
| 650 |
|
6 |
|a Chimie clinique.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 830 |
|
0 |
|a Issn Series.
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/bookseries/00652423/117
|z Connect to the full text of this electronic book
|t 0
|
| 936 |
|
|
|a BATCHLOAD
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 60579741-8774-4a41-b87b-810cea5dab73
|s ca57bd07-9532-479d-89dc-399914c349d7
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|h Library of Congress classification
|
| 998 |
f |
f |
|t 0
|l Available Online
|